Table 3.

Association between growth arrest‐specific gene 6 (Gas6) plasma level and venous thromboembolism (VTE) recurrence – from the time of the index VTE (T1) onwards using Gas6 measured at the time of VTE diagnosis (T1)

	n/N (%)	Crude subhazard ratio (95% confidence interval)	P‐value	Adjusted subhazard ratio (95% confidence interval)	P‐value
Up to 6 months
Gas6 at the time of the index VTE (categorized)
Low (< 109%)	2/216 (0.9)	Reference		Reference
Medium (109–157%)	11/435 (2.5)	2.77 (0.61–12.51)	0.185	2.95 (0.62–13.95)	0.172
High (> 157%)	11/213 (5.2)	5.74 (1.27–25.95)	0.023	6.65 (1.44–30.80)	0.015
Log‐transformed Gas6 at the time of the index VTE
Continuous (per log unit)	24/864 (2.8)	4.71 (1.98–11.19)	< 0.001	5.04 (2.14–11.88)	< 0.001
Up to 12 months
Gas6 at the time of the index VTE (categorized)
Low (< 109%)	8/216 (3.7)	Reference		Reference
Medium (109–157%)	23/435 (5.3)	1.46 (0.65–3.25)	0.355	1.50 (0.66–3.40)	0.335
High (> 157%)	17/213 (8.0)	2.26 (0.98–5.23)	0.056	2.42 (1.00–5.89)	0.051
Log‐transformed Gas6 at the time of the index VTE
Continuous (per log unit)	48/864 (5.6)	2.42 (1.12–5.24)	0.025	2.47 (1.08–5.64)	0.032

Adjustments: VTE recurrence was adjusted for age, cancer, provoked VTE, prior VTE, overt pulmonary embolism, renal disease and periods of anticoagulation (oral or parenteral anticoagulation) as a time‐varying covariate [6,41,44–52].